Letters, Statements & Analysis
AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.
On April 19, AMCP joined a pharmacy stakeholder letter addressed to the Biden administration's COVID-19 czar, Dr. Ashish Jha. The letter urged the Biden administration to allow qualified pharmacists to prescribe oral antivirals to treat COVID-19 and maintain PREP Act services provided by pharmacists.
On March 25, AMCP joined a diverse coalition of pharmacy stakeholders in expressing support for the Equitable Community Access for Pharmacists Services Act. This bill would permanently authorize pharmacists' ability to provide health care services during public health emergencies.
AMCP thanks the Senators and Congressmen on their leadership and introduction of the bipartisan, bicameral act.
On March 18, AMCP provided comments to the HHS Office of the National Coordinator for Health Information Technology regarding electronic prior authorization.
On March 9, AMCP joined 13 pharmacy organizations in urging President Biden to authorize pharmacists to order and administer oral antivirals to treat COVID-19 as part of the administration's Test to Treat policy.
AMCP provides feedback on CMS's proposal to redefine negotiated price as the lowest possible payment that a Part D plan will make to a pharmacy, inclusive of all price concessions.
On March 3, AMCP responded to a Request for Information from the Healthy Futures Subcommittee on Modernization, supporting legislative and regulatory solutions to remove barriers to coverage and payment for Digital Therapeutics in the Medicare program.
On Feb. 9, AMCP submitted comments to CMS supporting the agency's proposal to cover anti-amyloid monoclonal antibodies through the Coverage with Evidence Development pathway.
On Feb. 14, AMCP joined a pharmacy stakeholder letter supporting Dr. Robert Califf's nomination for FDA Commissioner, a post he previously held in 2016.
On Dec. 28, CMS released a proposed rule that would, in part, propose that adverse tiering is presumptively discriminatory and require that QHP issues offer more standardized plan options.
On Jan. 6, CMS released a proposed rule that would require pharmacy price concessions be passed to patients at the point-of-sale and reinstate detailed MLR reporting requirements.
On Jan. 11, CMS released a proposed coverage decision that would cover the costs of monoclonal antibody treatments for Alzheimer's Disease patients only if they are enrolled in clinical trials.
